About
Durin Life Sciences, Inc. was formerly known as Durin Technologies, Inc. Durin Life Sciences is a pioneering biotechnology company founded in 2010 with the goal of developing high-accuracy, minimally invasive, and easy-to-access tests for some of the most prevalent and devastating diseases. Since its inception, the company has secured 20 patents (12 granted and 8 provisional) and over $15 million in funding to develop and commercialize its Duritect™ tests. In 2025, Durin Life Sciences is launching its first two tests—Duritect-AD™ for Alzheimer’s disease (AD) and Duritect-PD™ for Parkinson’s disease (PD)—following a successful clinical validation process. Leveraging the immune system's autoantibodies with advanced machine learning technology, these innovative tests help physicians identify diseases earlier. With a scalable platform, Durin Life Sciences aims to extend beyond the neurodiagnostic market to address other devastating diseases.
Stratford